- Marketwired•3 months ago
Lixte Biotechnology Holdings, Inc. announced today the appointment of Stephen J. Forman, M.D., to the Board of Directors of Lixte. Dr. Forman is Director of the T cell Therapeutics Research Laboratory, ...
- Marketwired•7 months agoLixte Biotechnology Holdings, Inc.'s Lead Compound LB-100 Reported to Rapidly Improve Symptoms in a Rodent Model of Depression
Lixte Biotechnology Holdings, Inc. announced that neuroscientists at the French Institute of Health and Medical Research using a mouse model of depression have identified protein phosphatase 2A as a potential ...
- Marketwired•7 months ago
Lixte Biotechnology Holdings, Inc. announced today that a major shareholder has purchased $1,750,000 of Convertible Preferred stock. If fully converted, this purchase would convert to 2,187,500 common ...
Lixte Biotechnology Holdings, Inc. (LIXT)
Other OTC - Other OTC Delayed Price. Currency in USD
|Day's Range||0.00 - 0.00|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-4.00|
|Avg Vol (3m)||4,176|
|Dividend & Yield||N/A (N/A)|